Quest Diagnostics (DGX) stock surged 5.44% in pre-market trading on Tuesday following the release of its better-than-expected first-quarter 2025 financial results. The medical laboratory operator reported adjusted earnings per share of $2.21, surpassing analysts' estimates of $2.15, and revenue of $2.65 billion, exceeding expectations of $2.63 billion.
The company's impressive performance was driven by a robust 12.1% increase in revenue, including nearly 2.5% organic growth. Quest Diagnostics attributed this growth to contributions from acquisitions, large enterprise accounts, and increased demand for its advanced diagnostics portfolio. CEO Jim Davis noted that demand rebounded strongly in March following weather-related impacts early in the quarter.
Investors were particularly encouraged by Quest Diagnostics' decision to reaffirm its full-year 2025 revenue and adjusted EPS guidance. The company expects revenue between $10.70 billion and $10.85 billion, with adjusted earnings per share ranging from $9.55 to $9.80. This outlook, combined with the strong Q1 results, has bolstered investor confidence in Quest's ability to maintain its growth trajectory and navigate potential challenges in the healthcare diagnostics sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.